KYTX
Kyverna Therapeutics, Inc.Company Information
- Company Name
- Kyverna Therapeutics, Inc.
- CIK
- CIK0001994702
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- KYTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- KYTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-18
- Last sale
- 2025-12-15
- Shares purchased (TTM)
- 266,666
- Shares sold (TTM)
- 23,998
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 36,639,724
- Shares outstanding
- 60,896,872
- Ownership
- 60.17%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 2.87%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 32 | 32 | 124 | 34 | 53 | 57 | 97 | 105 | 132 | 224 | ||||||
| Marketable Securities Current | 168 | 204 | 155 | 137 | 158 | 186 | 189 | 217 | 215 | 146 | ||||||
| Prepaid Expense And Other Assets Current | 7 | 5 | 4 | 4 | 3 | 5 | 5 | 4 | 3 | 6 | ||||||
| Assets Current | 207 | 242 | 283 | 175 | 214 | 248 | 291 | 325 | 349 | 375 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | ||||||
| Operating Lease Right Of Use Asset | 8 | 8 | 4 | 4 | 5 | 6 | 6 | 7 | 8 | 8 | ||||||
| Finance Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | ||||||
| Other Assets Noncurrent | 3 | 5 | 5 | 5 | 4 | 4 | 3 | 2 | 1 | 1 | ||||||
| Assets | 220 | 257 | 294 | 187 | 227 | 261 | 305 | 339 | 363 | 390 | ||||||
Liabilities Current | ||||||||||||||||
| Accounts Payable Current | 3 | 12 | 5 | 3 | 10 | 8 | 5 | 10 | 5 | 7 | ||||||
| Accrued Employee Benefits Current | 5 | 3 | 10 | 7 | 5 | 3 | 5 | 4 | 3 | 1 | ||||||
| Operating Lease Liability Current | 1 | 2 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 23 | 30 | 36 | 34 | 40 | 33 | 34 | 31 | 23 | 22 | ||||||
| Operating Lease Liability Noncurrent | 7 | 7 | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 6 | ||||||
| Finance Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Long Term Line Of Credit | - | 25 | 25 | - | - | - | 0 | - | - | - | ||||||
| Long Term Debt Noncurrent | 25 | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 54 | 61 | 62 | 35 | 42 | 37 | 38 | 36 | 30 | 29 | ||||||
Stockholders Equity | ||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | - | - | - | 0 | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | - | - | - | 0 | - | - | - | ||||||
| Additional Paid In Capital Common Stock | 669 | 660 | 657 | 539 | 535 | 532 | 530 | 529 | 525 | 524 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -503 | -465 | -425 | -387 | -350 | -308 | -264 | -226 | -192 | -163 | ||||||
| Stockholders Equity | 166 | 196 | 232 | 152 | 184 | 224 | 267 | 303 | 334 | 361 | ||||||
| Liabilities And Stockholders Equity | 220 | 257 | 294 | 187 | 227 | 261 | 305 | 339 | 363 | 390 | ||||||
| Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | ||||||
| Common Stock Shares Issued | 62 | 61 | 60 | 44 | 43 | 43 | 43 | 43 | 43 | 43 | ||||||
| Shares Outstanding | 62 | 61 | 60 | 44 | 43 | 43 | 43 | 43 | 43 | 43 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKyverna Therapeutics, Inc. (KYTX) — SEC Financial Statements & Analysis
Kyverna Therapeutics, Inc. (KYTX) is a biological products, (no diagnostic substances) company, incorporated in DE. Kyverna Therapeutics, Inc. trades on Nasdaq as: KYTX. Kyverna Therapeutics, Inc. (KYTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Kyverna Therapeutics, Inc. carries a market cap of $542.59M, a P/E ratio of -3.55x, a P/B ratio of 3.28x, an enterprise value of $535.79M, and an EV/EBITDA multiple of -3.40x. On profitability, it posts a Return on Equity (ROE) of -87.24%, a Return on Assets (ROA) of -68.40%, and a Return on Invested Capital (ROIC) of -109.61%. Per share, it reports EPS of $-2.51, diluted EPS of $-2.51, free cash flow per share of $-2.61, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -3.82% year-over-year and EPS growth of -31.73% year-over-year. On the balance sheet, it maintains a current ratio of 9.06x, a quick ratio of 8.75x, working capital of $183.74M, a debt-to-equity ratio of 0.33x, a debt ratio of 0.25, an interest coverage ratio of -88.74x, free cash flow of $-159.05M (TTM), and net debt of $-6.80M. Figures sourced from SEC EDGAR.
- Market Cap
- $542.59M
- P/E TTM
- -3.55x
- EPS TTM
- $-2.51
- P/B TTM
- 3.28x
- ROE TTM
- -87.24%
- ROA TTM
- -68.40%
- Debt To Equity
- 0.33x
- Free Cash Flow TTM
- $-159.05M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Kyverna Therapeutics, Inc. in?
Kyverna Therapeutics, Inc. (KYTX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does KYTX trade on?
Kyverna Therapeutics, Inc. (KYTX) trades on the Nasdaq.
Where is Kyverna Therapeutics, Inc. incorporated?
Kyverna Therapeutics, Inc. is incorporated in DE.
When was Kyverna Therapeutics, Inc. (KYTX)'s most recent SEC filing?
Kyverna Therapeutics, Inc. (KYTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is KYTX's market cap?
Kyverna Therapeutics, Inc. (KYTX) has a market capitalization of $542.59M as of 2026-06-30.
What is KYTX's EPS (earnings per share)?
Kyverna Therapeutics, Inc. (KYTX)'s trailing twelve month EPS is $-2.51 as of 2026-06-30.
What is KYTX's ROE (return on equity)?
Kyverna Therapeutics, Inc. (KYTX)'s trailing twelve month Return on Equity (ROE) is -87.24% as of 2026-06-30.
What is KYTX's ROA (return on assets)?
Kyverna Therapeutics, Inc. (KYTX)'s trailing twelve month Return on Assets (ROA) is -68.40% as of 2026-06-30.
What is KYTX's ROIC (return on invested capital)?
Kyverna Therapeutics, Inc. (KYTX)'s trailing twelve month Return on Invested Capital (ROIC) is -109.61% as of 2026-06-30.
What is KYTX's EV/EBITDA?
Kyverna Therapeutics, Inc. (KYTX)'s trailing twelve month EV/EBITDA is -3.40x as of 2026-06-30.